top of page

Hope or Hype? Psychedelic-Assisted Therapy for Treatment-Resistant Depression


In a world where traditional treatments for depression often fall short, psychedelics may offer hope on the horizon. Psychedelic-assisted therapy has gained increasing attention as a potential breakthrough for individuals with treatment-resistant depression. This blog post aims to explore the efficacy, science, patient testimonials, and expert opinions surrounding psychedelic-assisted therapy, focusing on two key substances: Ketamine and Psilocybin.

What is Treatment-Resistant Depression?

Treatment-Resistant Depression (TRD) is a term used to describe cases of major depressive disorder that do not show an adequate response to at least two different antidepressants from different drug classes, at the right dose, for a sufficient duration, and followed by an adequate trial of augmentation strategies. According to the World Health Organization, depression affects over 300 million people worldwide, and it's estimated that 10-30% of these individuals may suffer from TRD.

While many people respond well to psychotropic medications, they do have limitations when treating TRD. Antidepressants can often involve a trial-and-error process to find an effective drug, may take weeks to take effect, and can cause significant side effects. For many individuals, these medications simply don't work, leading to ongoing struggles with depression.

Innovative Treatment with Psychedelics

One of the amazing ways psychedelics work is by unlocking new pathways of healing and self-discovery. Where current brain pathways are "stuck in a rut" or wired into rigid patterns and beliefs, psychedelics exponentially increase new neural pathways and loosen rigid thought structures.

An additional benefit of these medicines is the ability to delve into past traumas that may contribute to depression. Through ongoing integration therapy, individuals can process and integrate traumatic memories in a safe and supportive environment. This approach allows for deeper healing, leading to improved mental health outcomes.

Empirical Evidence Supporting Psychedelic-Assisted Therapy

Studies highlight the ability of Ketamine (a dissociative anesthetic and Psilocybin, the active component of "magic mushrooms" to induce transformative experiences, enhance brain plasticity, and alleviate depressive symptoms.

  • A study released in Nature Medicine (2021) demonstrated that psilocybin-assisted therapy had a significantly higher response and remission rates at the one-week follow-up than a common antidepressant, escitalopram.

  • Furthermore, a double-blind study conducted by The American Journal of Psychiatry (2020) showed the rapid and sustained antidepressant effects of a single dose of ketamine in patients with treatment-resistant depression.

  • Finally, a comprehensive review published in Psychopharmacology (2020) of multiple clinical trials highlighted the safety and efficacy of psilocybin for various psychiatric disorders, including depression, anxiety, and substance-use disorders.

Expert Opinions

Perspectives from experts in the fields of psychiatry and psychology further illuminate the potential of psychedelic-assisted therapy. These professionals offer insights into the neurobiological mechanisms, therapeutic frameworks, and the unique role these treatments can play in addressing treatment-resistant depression. They also discuss potential limitations and ongoing research efforts.

  • Dr. Robin Carhart-Harris, Head of the Centre for Psychedelic Research, Department of Brain Sciences at Imperial College London, argues that "Psilocybin therapy might offer longer-term relief from the symptoms of depression". Dr. Carhart-Harris further adds, "These findings provide further support for the growing evidence base that shows that, in people with depression, psilocybin offers an alternative treatment to traditional antidepressants."

  • Meanwhile, Dr. Stephen Ross, Associate Professor of Psychiatry at NYU School of Medicine, suggests that psychedelic therapy could be a paradigm shift for psychiatric medicine. "The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market," adding that "psychedelics have a potentially revolutionary effect on contemporary psychiatry."

  • Finally, Dr. Michael Bogenschutz, a psychiatrist at New York University who studies alcohol addiction, believes that these kinds of treatments could be a significant step forward. He says, "for treatment-resistant depression, psychedelic therapy could be the 'next big thing' in psychiatric treatment."

Addressing Concerns and Considerations

As with any therapeutic intervention, concerns and considerations must be addressed. Safety measures, precautions, and ethical considerations are crucial aspects to navigate. Additionally, the legal status of psychedelic substances is a topic of ongoing discussion and has implications for accessibility and research.


Balancing hope and hype, psychedelic-assisted therapy offers a ray of light for individuals grappling with treatment-resistant depression. While the potential benefits are promising, further research and robust clinical trials are essential to establish evidence-based protocols and ensure responsible implementation. As we continue to explore new frontiers in mental health treatments, psychedelic-assisted therapy holds promise as a beacon of hope for those in need.

Disclaimer: This blog post is for informational purposes only and does not constitute medical advice. It is essential to consult with healthcare professionals before considering any treatment options for depression or mental health conditions.

You deserve to heal. Psychedelics can be a safe alternative to traditional methods, but they are not for everyone. Please be aware of legalities related to psychedelics in your particular jurisdiction.

If you are looking for safe psychedelic-assisted therapy and journeys, please contact me at 

Informational Resources:

Carhart-Harris, R. et al., 2021. A randomized controlled trial of psilocybin for major depressive disorder. New England Journal of Medicine.

Ross, S. et al., 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology.

Bogenschutz, M.P. et al., 2018. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology

1 view0 comments
bottom of page